Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care to Invest in Its Stem-Cell Subsidiary Unicyte

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/05/2019 | 05:37am EDT

By Max Bernhard

Fresenius Medical Care AG & Co. KGaA (FME.XE) said Thursday that it plans to invest 60 million euros ($66.0 million) in its stem-cell technology subsidiary Unicyte.

FMC said it plans to make the investment in a series A financing round and that Unicyte will use the money to start clinical trials of its first product candidates in 2020 and to establish the necessary manufacturing processes.

Unicyte, which is fully owned by FMC, focuses on kidney and liver disorders.

"Driving regenerative therapies not only addresses the U.S. administration's initiative to improve the prevention of end-stage renal disease, but can help us to significantly slow the progression of kidney disease and make the most innovative therapies available to our patients," said Rice Powell, CEO of Fresenius Medical Care.

Write to Max Bernhard at max.bernhard@dowjones.com; @mxbernhard

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.96% 63 Delayed Quote.11.23%
FRESENIUS SE & CO. KGAA 1.16% 45.69 Delayed Quote.7.81%
ROUGH RICE FUTURES (ZR) - CBE (ELECTRONIC)/C1 0.49% 12.24 End-of-day quote.17.34%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS MEDICAL CARE AG
09/10FRESENIUS6CPRF : Fresenius Medical Care's annual medical report explores how Int..
AQ
09/09FRESENIUS MEDICAL CARE : annual medical report explores how Interconnected Intel..
PU
09/09FRESENIUS MEDICAL CARE : Spectra Laboratories - Fresenius Medical Care builds ne..
AQ
09/09FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
09/06FRESENIUS MEDICAL CARE : Builds New Laboratory in US
DJ
09/05Fresenius Medical Care to Invest in Its Stem-Cell Subsidiary Unicyte
DJ
09/03Fresenius Helios Acquires Two Hospitals in Colombia
DJ
09/02FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
08/31FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the Wp..
EQ
08/28FRESENIUS6CPRF : Fresenius Medical Care appoints Helen Giza as Chief Financial O..
AQ
More news
Financials (USD)
Sales 2019 19 373 M
EBIT 2019 2 591 M
Net income 2019 1 298 M
Debt 2019 9 277 M
Yield 2019 1,83%
P/E ratio 2019 16,2x
P/E ratio 2020 13,7x
EV / Sales2019 1,58x
EV / Sales2020 1,45x
Capitalization 21 261 M
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 87,36  $
Last Close Price 69,75  $
Spread / Highest target 58,6%
Spread / Average Target 25,3%
Spread / Lowest Target -29,4%
EPS Revisions
Managers
NameTitle
Rice Powell Chief Executive Officer
Dieter Schenk Chairman-Supervisory Board
Michael Brosnan Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
William P. Johnston Member-Supervisory Board